Please assess the completion status of the following clinical trial:

Trial Title: Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with relapsed or refractory Mantle Cell lymphoma with measurable disease.~* Age \> 18 years old~* Expected survival \>/= 3 months~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 at initiation of study (Appendix I).~* Laboratory tests meet the levels specified in the protocol~Exclusion Criteria:~* Patients must not have received chemotherapy, radiation or surgical resection of malignancy within 3 weeks of study initiation. However, if they have received nitrosurea or mitomycin C then they should not be enrolled in the study until 6 weeks after therapy was last received.~* No limitations to number of prior therapies~* No prior radioimmunotherapy (RIT)~* Prior bortezomib is allowed~* Patient must be fully recovered from all toxicities associated with prior surgery, radiation treatment, chemotherapy or immunotherapy.~* No active, serious infection or medical or psychiatric illness likely to interfere with participation in this clinic trial~* No known HIV infection~* No active central nervous system (CNS) involvement~* Bone Marrow Involvement \>/= 25% within 30 days of initiation of study treatment~* Pregnant or breast feeding~* No patients who have received Granulocyte colony-stimulating factor (G-CSF) or Granulocyte macrophage colony-stimulating factor (GM-CSF) within the 14 days prior to initiating protocol~* No patient who has had major surgery within the four weeks prior to initiating protocol therapy~* No patients with pleural effusion or significant ascites

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zevalin + Velcade (Type: EXPERIMENTAL): Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan~Other Names:~Rituxan Velcade Zevalin~Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4 millicurie (mCi)/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi.

Based on this trial design, predict the completion outcome and termination type (if applicable).